Immunodiffusion and fluorescent antibody methods to distinguish rod from coccoid forms of a species ofArthrobacter

A. Holland,T. Gray,B. M. Luscombe

DOI: https://doi.org/10.1007/BF02328089

Antonie van Leeuwenhoek

Abstract:

What problem does this paper attempt to address?

Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea

Chang-Hoon Lee,Mi-Sook Kim,See-Hwee Yeo,Chin-Kook Rhee,Heung-Woo Park,Bo-Ram Yang,Joongyub Lee,Eun-Yeong Cho,Xiaomeng Xu,Aldo Amador Navarro Rojas,Sumitra Shantakumar,Dominique Milea,Nam-Kyong Choi

DOI: https://doi.org/10.1186/s12931-022-02136-0

2022-09-05

Abstract:Background: Multiple inhaler triple therapy (MITT), comprising inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), and long-acting muscarinic antagonists (LAMA), has been used as an escalation treatment for patients with chronic obstructive pulmonary disease (COPD). However, real-world use of MITT has not been investigated in Asia, including South Korea. This study reports baseline characteristics of patients with COPD initiated on MITT in South Korea, and their treatment patterns. Healthcare resource utilization (HRU) and costs associated with COPD exacerbations following MITT initiation were also assessed. Methods: This was a retrospective cohort study using the South Korea National Health Insurance database (2014-2018). Included patients were ≥ 40 years, had a COPD diagnosis, were newly initiated on MITT and had ≥ 12 months' data both before (baseline) and after index date (the first day with overlapping supply of all MITT components). Treatment immediately before initiation and immediately following discontinuation of MITT were identified, and proportion of days covered (PDC) by MITT was calculated. HRU and costs (per person per year [PPPY]) associated with exacerbations were identified following MITT initiation; costs were calculated using the average 2020 exchange rate (0.0008 USD/KRW). Results: Among 37,400 patients, the mean age was 69 (SD 10) years and 73% were males; 56% had ≥ 1 COPD exacerbation during the baseline period, with a mean of 2 (SD 5) events/year. ICS/LABA was the most frequent regimen prescribed immediately before initiation (37%) and immediately following discontinuation (41% of 34,264 patients) of MITT. At 3, 6, and 12 months from treatment initiation, mean PDC was 81%, 63% and 49%, respectively; median treatment duration was 102 days. The mean (95% confidence interval [CI]) number of total visits for severe COPD exacerbations was 0.77 PPPY (0.75-0.78); mean PPPY total healthcare costs were 2093 USD. Conclusions: Patients with COPD in South Korea experienced frequent exacerbations prior to MITT, and PDC by MITT was low. Patients may benefit from early optimization of COPD therapy, and greater emphasis on adherence to inhaled COPD therapy. Severe exacerbations were found to incur substantial costs; treatment alternatives that can reduce the rate of severe exacerbations are likely to minimize healthcare costs.
Escalation Time to Open Triple Combination Therapy from the Initiation of LAMA versus ICS/LABA in COPD Management: Findings from Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea (CITRUS) Study

Ye Jin Lee,Chin Kook Rhee,Yong Il Hwang,Kwang Ha Yoo,So Eun Lee,Doik Lee,Yong Bum Park,Youlim Kim

DOI: https://doi.org/10.3390/jpm11121325

IF: 3.5083

2021-12-07

Journal of Personalized Medicine

Abstract:Background: bronchodilators are the key treatment for chronic obstructive pulmonary disease (COPD), however, inhaled corticosteroids (ICSs)/long-acting β2-agonists (LABA) are widely prescribed. We compared the escalation time to open triple combination therapy between long-acting muscarinic receptor antagonists (LAMA) and ICS/LABA in COPD management. Methods: this retrospective study included COPD patients selected from the National Health Insurance Service of South Korea from January 2005 to April 2015. The primary outcome was the escalation time to triple therapy in patients who initially received LAMA or ICS/LABA. Other outcomes included risk factors predisposing escalation to triple combination therapy. Results: a total of 2444 patients were assigned to the LAMA or ICS/LABA groups. The incidences of triple combination therapy in the LAMA and ICS/LABA groups were 81.0 and 139.8 per 1000 person-years, respectively (p < 0.001); the median times to triple therapy escalation were 281 and 207 days, respectively (p = 0.03). Treatment with ICS/LABA showed a higher risk of triple therapy escalation compared to LAMA (hazard ratio (HR), 1.601; 95% confidence interval (CI), 1.402–1.829). The associated risk factor was male sex. (HR, 1.564; 95% CI, 1.352–1.809). Conclusions: the initiation of COPD treatment with LAMA is associated with a reduced escalation time to triple therapy compared with ICS/LABA.

medicine, general & internal,health care sciences & services
A note on certain cranial indices of the Sterkfontein skull No. 5.

W. E. Clark

DOI: https://doi.org/10.1002/AJPA.1330100121

1952-03-01

American Journal of Physical Anthropology

Abstract:
The current status of chronic obstructive pulmonary disease awareness, treatments, and plans for improvement in South Korea: a narrative review

Yong Bum Park,Kwang Ha Yoo

DOI: https://doi.org/10.21037/jtd-21-172

2021-06-01

Journal of Thoracic Disease

Abstract:The prevalence of chronic obstructive pulmonary disease (COPD) is high in South Korea which has remained virtually unchanged over the past few years. Other challenges related to COPD in South Korea include a low level of awareness of COPD, underutilization of pulmonary function tests (PFTs) and a low level of inhaler use. Continued efforts have been made to raise awareness of COPD in the general public and promote screening tests for the early detection of COPD patients for high-risk patients, which should be the primary object for better management of the disease. The Korean Academy of Tuberculosis and Respiratory Diseases (KATRD) and the Korea Disease Control and Prevention Agency (KDCA) have been working in tandem on numerous projects to resolve these issues. As the fruit of these efforts, a couple of projects are currently being carried out to add PFTs into the National Health Examination (NHE) of Korea as part of screening tests and improve the quality of COPD treatments in primary care settings. Raising public awareness of a chronic disease such as COPD requires collective efforts of academic societies and government. In addition, personalized education programs that are tailored to individual COPD patients is a necessity to raise adherence of treatment and self-management of COPD. The aim of this manuscript is to report the current status of COPD management in South Korea in hopes that it will help better treat and manage COPD in other nations coping with similar challenges.

respiratory system
The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease

Ji Won Park,Yoonki Hong,Chin Kook Rhee,Hye Sook Choi,Kyungjoo Kim,Kwang Ha Yoo,Ki-Suck Jung,Joo Hun Park

DOI: https://doi.org/10.2147/COPD.S388367

2023-05-02

International Journal of COPD

Abstract:Ji Won Park, 1, &ast Yoonki Hong, 2, &ast Chin Kook Rhee, 3 Hye Sook Choi, 4 Kyungjoo Kim, 3 Kwang Ha Yoo, 5 Ki-Suck Jung, 6 Joo Hun Park 1 1 Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, South Korea; 2 Department of Internal Medicine, Kangwon National University, Chuncheon, South Korea; 3 Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; 4 Department of Internal Medicine, Kyung Hee University Medical Center, Seoul, South Korea; 5 Department of Internal Medicine, Konkuk University School of Medicine, Seoul, South Korea; 6 Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea &astThese authors contributed equally to this work Correspondence: Joo Hun Park, Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Worldcup road 164, Suwon, Gyeonggi-do, 16499, South Korea, Tel +82-31-219-5116 ; +82-10-8379-8299, Fax +82-31-219-5124, Email ; Background: A comprehensive analysis of the effects of inhaled corticosteroids (ICS) on COPD in a real-world setting is required due to safety concerns regarding ICS in COPD. This study aimed to explore the impact of ICS on the prognosis of Asian COPD patients in the real-life world. Methods: We examined 978 COPD patients registered in the Korean National Health and Nutrition Examination Survey (KNHANES) database and with their data linked to Health Insurance and Review Assessment (HIRA) data. The outcome measures were ascertained by HIRA from January 1, 2009, to December 31, 2012. This study enrolled two arms; ICS users (N = 85, mean age = 66.7 ± 8.9 years) and non-ICS users (N = 893, mean age = 63.7 ± 9.7 years). Results: Compared to the non-ICS users, the ICS users had a higher rate of pneumonia, tuberculosis, and acute exacerbations ( P < 0.05). Hospitalization due to respiratory causes was also higher among ICS users ( P < 0.05). Multivariate analysis showed that acute exacerbation was independently associated with the development of pneumonia ( P < 0.05), whereas ICS therapy had a tendency to be associated with pneumonia. Another multivariate analysis demonstrated that old age, FEV 1 , ICS therapy, and pneumonia were independently associated with the occurrence of acute exacerbation ( P < 0.05). The concomitant pneumonia (HR = 3.353, P = 0.004) was independently associated with higher mortality ( P < 0.05). Conclusion: Our data demonstrated that the ICS users had a higher rate of pneumonia and tuberculosis and the concomitant pneumonia was independently associated with higher mortality, highlighting the importance of cautious and targeted administration of ICS in COPD. Keywords: COPD, inhaled corticosteroids, pneumonia, mortality Although chronic obstructive pulmonary disease (COPD) has been a major public health concern and was expected to rank third among all the causes of death by 2030, there is still no therapeutic intervention that modifies the natural course of COPD. 1,2 The pharmacological treatment of COPD comprises long-acting muscarinic antagonist (LAMA), long-acting beta-agonists (LABA), the combination of LAMA and LABA, the combination of LABA and inhaled corticosteroids (ICS), and triple therapy including LABA, LAMA, and ICS. The benefits of ICS in COPD reported by various studies include the reduction of frequency of COPD exacerbations, a lower rate of hospitalization, and a reduction of all-cause mortality in some COPD subgroups. 3–6 However, the use of ICS in COPD is much debated because of the associated safety concerns; 7–10 there is a concern about the attendant side effects of ICS on COPD including pneumonia and tuberculosis. 11,12 Consequently, the withdrawal of ICS in COPD patients is common due to ICS-related adverse events or treatment-related risks outweighing the expected benefits. 13,14 In addition, ICS treatment is associated with several challenges; observational studies suggested that overprescription of ICS is common in patients with COPD and smoking can result in steroid resistance by decreasing the efficacy of ICS in COPD. 13,15,16 However, so far, there are few comprehensive analyses of the effects of ICS on COPD in a real-world setting. Hence, this study was conducted to investigate the impact of ICS on the prognosis of Asian COPD patients in the real world setting by analyzing the Korean National Health and Nutrition -Abstract Truncated-

respiratory system
The effects of different inhalation therapies on less symptomatic chronic obstructive pulmonary disease patients in a Chinese population: a real-world study

Qing Song,Ling Lin,Aiyuan Zhou,Wei Cheng,Cong Liu,Yating Peng,Zijing Zhou,Yuqin Zeng,Dingding Deng,Dan Liu,Zhiping Yu,Yan Chen,Shan Cai,Ping Chen

DOI: https://doi.org/10.1080/07853890.2023.2192519

IF: 5.348

2023-03-31

Annals of Medicine

Abstract:The Global Initiative for Chronic Obstructive Lung Disease (GOLD) document suggests that patients with chronic obstructive pulmonary disease (COPD) should be divided into a less symptomatic group. Moreover, single-inhaled drugs are recommended as initial inhalation therapy for them. However, many less symptomatic patients are provided double or triple-inhaled drugs as initial therapy in the real world. This study aimed to describe the inhalation prescriptions and compare the effects of different inhalation therapies on less symptomatic COPD patients. This was an observational study. Stable COPD patients were recruited and divided into a less symptomatic group including Groups A and C based on the GOLD 2019 document. We collected the data of inhalation therapies prescriptions. Then, the patients were classified into long-acting muscarinic antagonist (LAMA), long-acting β2-agonist (LABA) + inhaled corticosteroid (ICS), LABA + LAMA, and LABA + LAMA + ICS groups. All the patients were followed up for 1 year to collect exacerbation and mortality data. We found that only 45.4% of patients in Group A and 43.6% of patients in Group C received reasonable inhalation therapy in reference to the GOLD document. In addition, the LAMA group had a higher forced expiratory volume in one second (FEV1), FEV1%pred, FEV1/forced vital capacity and peak expiratory flow compared with LABA + ICS, LABA + LAMA and LABA + LAMA + ICS groups. However, we did not find any significant differences of exacerbation, hospitalization and mortality during the follow-up among different inhalation therapies groups on less symptomatic COPD patients. Over half of the less symptomatic patients received inhalation therapy that were inconsistent with the GOLD document recommendations in a Chinese population in the real world. In fact, the single inhaled drug of LAMA should be recommended and pulmonary function is not a good indicator for the choice of initial inhalation therapy in less symptomatic COPD patients. Over half of the less symptomatic COPD patients received inhalation therapy that were inconsistent with the GOLD document recommendations in a Chinese population in the real world. The clinicians should offer a single inhaled drug of LAMA to less symptomatic COPD patients and pulmonary function is not a good indicator for the choice of initial inhalation therapy.

medicine, general & internal
Real-World Effectiveness of Inhalation Therapy Among Patients With Symptomatic COPD in China: A Multicenter Prospective Study

Wei Cheng,Jiaxi Duan,Aiyuan Zhou,Yiyang Zhao,Rong Yi,Yi Liu,Dingding Deng,Xin Li,Yuqin Zeng,Yating Peng,Qing Song,Ling Lin,Min Yang,Ping Chen

DOI: https://doi.org/10.3389/fphar.2021.753653

IF: 5.6

2021-09-21

Frontiers in Pharmacology

Abstract:Purpose: This real-world study evaluated the effectiveness of different inhalation therapies in patients with symptomatic chronic obstructive pulmonary disease (COPD) in China and also explored the relevant factors that influence the effectiveness of inhalation therapy. Patients and Methods: We conducted a multicenter prospective longitudinal study that was carried out in 12 hospitals in China from December 2016 to June 2021. A face-to-face interview was conducted to collect data. Baseline data were collected at the first visit. Minimum clinically important difference (MCID) was defined as attaining a COPD assessment test (CAT) decrease ≥2. We mainly assessed the MCID and the incidence of exacerbations at the 6 months follow-up. Results: In 695 patients, the mean age was 62.5 ± 8.2 years, with a mean CAT score of 15.1 ± 6.0. Overall, 341 (49.1%) patients attained the MCID of CAT and the incidence of exacerbation during follow-up was 22.3%. Females were significantly more likely to attain MCID than male in COPD patients (adjusted odd ratio (aOR) = 1.93, adjusted 95% confidence interval (a95%CI) = 1.09–3.42, p = 0.024). Patients treated with LABA/LAMA or ICS/LABA/LAMA (ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist) were more likely to attain MCID than patients treated with LAMA (aOR = 3.97, a95%CI = 2.48–6.35, p < 0.001; aOR = 3.17, a95%CI = 2.09–4.80, p < 0.001, respectively). Patients treated with LABA/LAMA had a higher incidence of severe exacerbation than patients treated with ICS/LABA/LAMA (aOR = 1.95, a95%CI = 1.04–3.66, p = 0.038). Conclusion: The incidence of MCID in symptomatic COPD patients treated with inhalation therapy was nearly 50%. Patients treated with LABA/LAMA or ICS/LABA/LAMA were more likely to attain MCID than patients treated with LAMA. Patients treated with LABA/LAMA had a higher incidence of severe exacerbations than with ICS/LABA/LAMA.

pharmacology & pharmacy
Treatment patterns in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)

Ting Yang,Baiqiang Cai,Bin Cao,Jian Kang,Fuqiang Wen,Yahong Chen,Wenhua Jian,Chen Wang

DOI: https://doi.org/10.1177/17534666231158283

Abstract:Background: Underdiagnosis and undertreatment pose major barriers to optimal management of chronic obstructive pulmonary disease (COPD) in China. Objective: The REAL trial was performed to generate reliable information on real-world COPD management, outcomes and risk factors among Chinese patients. Here, we present study outcomes related to COPD management. Design: It is a 52-week, prospective, observational, multicentre study. Methods: Outpatients (aged ⩾40 years) enrolled from 50 secondary and tertiary hospitals across six geographic regions of China were followed up for 12 months, with two onsite visits and by telephone every 3 months following baseline. Results: Between June 2017 and January 2019, 5013 patients were enrolled and 4978 included in the analysis. Mean [standard deviation (SD)] age was 66.2 (8.9) years, the majority of patients were male (79.5%) and mean (SD) time since COPD diagnosis was 3.8 (6.2) years. The most common treatments at each study visit were inhaled corticosteroids/long-acting beta-agonists (ICSs/LABAs; 28.3-36.0%), long-acting muscarinic antagonists (LAMAs; 13.0-16.2%) and ICS/LABA + LAMA (17.5-18.7%), but up to 15.8% of patients at each visit received neither ICS nor long-acting bronchodilators. The use of ICS/LABA, LAMA and ICS/LABA + LAMA differed across regions and hospital tiers; up to fivefold, more patients received neither ICS nor long-acting bronchodilators in secondary (17.3-25.4%) versus tertiary hospitals (5.0-5.3%). Overall, rates of nonpharmacological management were low. Direct treatment costs increased with disease severity, but the proportion of direct treatment costs incurred due to maintenance treatment decreased with disease severity. Conclusion: ICS/LABA, LAMA and ICS/LABA + LAMA were the most frequently prescribed maintenance treatments for patients with stable COPD in China, although their use differed between region and hospital tier. There is a clear need for improved COPD management across China, particularly in secondary hospitals. Registration: The trial was registered on 20 March 2017 (ClinicalTrials.gov identifier: NCT03131362; https://clinicaltrials.gov/ct2/show/NCT03131362). Plain language summary: Treatment patterns in patients with COPD in ChinaBackground: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by progressive and irreversible airflow limitation. In China, many patients with this disease do not receive a diagnosis or appropriate treatment.Objective: This study aimed to generate reliable information on the treatment patterns among patients with COPD in China to help inform future management strategies.Study design and methods: Patients (aged ⩾40 years) were enrolled from 50 hospitals across 6 regions of China and physicians collected data over the course of 1 year during routine outpatient visits.Results: The majority of patients were receiving long-acting inhaled treatments, which are recommended to prevent worsening of the disease. Up to 16% of patients in this study, however, did not receive any of these recommended treatments. The proportion of patients who received long-acting inhaled treatments differed across regions and hospital tiers; there were about five times more patients in secondary hospitals (about 25%) who did not receive these treatments compared with those in tertiary hospitals (about 5%). Guidelines recommend that pharmacological treatment should be complemented by nondrug treatment, but this was only received by a minority of patients in this study. Patients with higher disease severity incurred greater direct treatment costs compared with those with milder disease. Maintenance treatment costs made up a smaller proportion of overall direct costs for patients with higher disease severity (60-76%) compared with patients with milder disease (81-94%).Conclusion: Long-acting inhaled treatments were the most frequently prescribed maintenance treatments among patients with COPD in China, but their use differed between region and hospital tier. There is a clear need to improve disease management across China, especially in secondary hospitals.
Neues zu den diätetischen Schriften des Rufus von Ephesos.

M. Ullmann

Abstract:
Overuse of long-acting β2-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns

Stephen A Brunton,D Kyle Hogarth

DOI: https://doi.org/10.1080/00325481.2023.2284650

Abstract:Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality globally. In the major revision of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 report, the scientific committee concluded that the use of long-acting β2-agonist/inhaled corticosteroids (LABA/ICS) is not encouraged in patients with COPD. However, current prescribing patterns reveal significant use of LABA/ICS. In this paper, the evidence behind the current practice and the latest treatment recommendations is reviewed. We compare the efficacy and safety of combination therapy with long-acting muscarinic antagonist (LAMA) and LABA vs LABA/ICS and note that LAMA/LABA combinations have reduced the annual rate of moderate/severe exacerbations, delayed the time to first exacerbation, and increased post-dose FEV1 vs ICS-based regimens. The GOLD 2023 report recommends treatment with LABA and LAMA combination (preferably as a single inhaler) in patients with persistent dyspnea, with initiation of ICS in patients based on the symptoms (dyspnea and exercise intolerance as indicated by modified Medical Research Council [mMRC] score ≥ 2 and COPD Assessment Test [CAT™] > 20), blood eosinophil count (≥ 300 cells/µL), and exacerbation history (history of hospitalizations for exacerbations of COPD and ≥ 2 moderate exacerbations per year despite appropriate long-acting bronchodilator maintenance therapy). We describe practical recommendations for primary care physicians to optimize therapy for their patients and prevent overuse of ICS-based regimens. We advocate adherence to current recommendations and a greater focus on effective treatments to successfully control symptoms, minimize exacerbation risk, preserve lung function, maximize patient outcomes, and reduce the burden of drug-related adverse events.
Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world study

Kevin Gruffydd-Jones,Guy Brusselle,Rupert Jones,Marc Miravitlles,Michael Baldwin,Rebecca Stewart,Anna Rigazio,Emily Davis,Dorothy L Keininger,David Price

DOI: https://doi.org/10.1038/npjpcrm.2016.2

2016-02-25

npj Primary Care Respiratory Medicine

Abstract:Prescribing patterns in chronic obstructive pulmonary disease (COPD) are often inconsistent with published guidelines. This retrospective, observational study utilised data from the Optimum Patient Care Research Database to examine the changes in COPD prescribing patterns over time and to identify predictors of physician treatment choice for patients newly diagnosed with COPD. Initial therapy was defined as the treatment(s) prescribed at or within 1 year before COPD diagnosis. Changes over time were assessed in three cohorts based on the date of diagnosis: (1) 1997–2001; (2) 2002–2006; and (3) 2007–2010. Factors affecting the odds of being prescribed any initial therapy or any initial maintenance therapy were identified by univariable and multivariable logistic regression. The analysis included 20,154 patients, 45% of whom were prescribed an initial regimen containing an inhaled corticosteroid (ICS), whereas 28% received no initial pharmacological treatment. Prescribing of ICS monotherapy decreased over time, as did the proportion of patients receiving no therapy at or within 1 year before diagnosis. Comorbid asthma, a high exacerbation rate, increased symptoms and poor lung function each increased the likelihood of being prescribed any initial therapy or initial maintenance therapy; comorbid asthma and an annual rate of ⩾3 exacerbations were the strongest predictors. In conclusion, our analyses revealed major differences between actual prescribing behaviour and guideline recommendations for patients with newly diagnosed COPD, with many patients receiving no treatment and large numbers of patients receiving ICS-containing regimens. Predictors of initial therapy were identified.

primary health care,respiratory system
Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea

Ji-Yong Moon,Sang Hyuk Kim,Youlim Kim,Hyun Lee,Chin Kook Rhee,Seung Won Ra,Chang Youl Lee,Joo Hun Park,Yong Bum Park,Kwang Ha Yoo

DOI: https://doi.org/10.1016/j.pupt.2024.102298

Abstract:Background: A suboptimal peak inspiratory flow rate (PIFR) in dry-powder inhaler (DPI) users can lead to insufficient therapeutic effects in the treatment of chronic obstructive pulmonary disease (COPD). However, few data on the prevalence of and factors associated with suboptimal PIFR in Korean patients with COPD are available. Methods: We conducted a cross-sectional study of patients with COPD who had been using DPIs for more than three months. PIFR was measured using an In-Check DIAL G16 device. Suboptimal PIFR was defined as below the resistance-matched threshold. Multivariable logistic regression analysis was used to determine factors associated with suboptimal PIFR. Results: Of 444 DPI users with COPD, the rate of suboptimal PIFR was 22.0 % (98/444). In a multivariable analysis, significant factors associated with suboptimal PIFR were age (adjusted odds ratio [aOR] = 1.06 by 1-year increase; 95 % confidence interval [CI] = 1.02-1.09), male sex (aOR = 0.28; 95 % CI = 0.11-0.73), body mass index (BMI) (aOR = 0.91 by 1 kg/m2 increase; 95 % CI = 0.85-0.99), post-bronchodilator forced vital capacity (FVC) %pred (aOR = 0.97 by 1%pred increase; 95 % CI = 0.95-0.99), and In-Check DIAL R2-type inhaler [medium-low resistance] use (aOR = 3.70 compared with R1-type inhalers [low resistance]; 95 % CI = 2.03-7.03). Conclusions: In Korea, more than one-fifth of DPI users with COPD had a suboptimal PIFR. The factors associated with suboptimal PIFR were age, female gender, low BMI, low FVC, and R2-type inhaler use. Therefore, clinicians should carefully evaluate the possibility of suboptimal PIFR when prescribing DPIs.
Korean physician prescription patterns for home oxygen therapy in chronic obstructive pulmonary disease patients

Youlim Kim,Hwan Il Kim,Ji Young Park,Ji Young Hong,Joo-Hee Kim,Kyung Hoon Min,Chin Kook Rhee,Sunghoon Park,Chang Youl Lee,Seong Yong Lim,Seung Hun Jang,Yong Il Hwang

DOI: https://doi.org/10.3904/kjim.2020.470

2022-01-01

The Korean Journal of Internal Medicine

Abstract:Background/Aims: Hypoxemia in chronic obstructive pulmonary disease (COPD) leads to reduced ability to exercise, decreased quality of life, and, eventually, increased mortality. Home oxygen therapy in patients with severe COPD reduces distress symptoms and mortality rates. However, there have been few studies on physicians’ prescription behavior toward home oxygen therapy. Therefore, we investigated the respiratory specialists’ perspective on home oxygen therapy.Methods: In this cross-sectional, study, a questionnaire was completed by 30 pulmonary specialists who worked in tertiary hospitals and prescribed home oxygen therapy. The questionnaire consisted of 28 items, including 15 items on oxygen prescription for outpatients, four for inpatients, and nine on service improvement.Results: All physicians were prescribing less than 2 L/min of oxygen for either 24 (n = 10, 33.3%) or 15 hours (n = 9, 30.3%). All (n = 30) used pulse oximetry, 26 (86.7%) analyzed arterial blood gas. Thirteen physicians had imposed restrictions and recommended oxygen use only during exercise or sleep. Sixteen (53.3%) physicians were educating their patients about home oxygen therapy. Furthermore, physicians prescribed home oxygen to patients that did not fit the typical criteria for longterm oxygen therapy, with 30 prescribing it for acute relief and 17 for patients with borderline hypoxemia.Conclusions: This study identified the prescription pattern of home oxygen therapy in Korea. Respiratory physicians prescribe home oxygen therapy to hypoxemic COPD patients for at least 15 hours/day, and at a rate of less than 2 L/min. More research is needed to provide evidence for establishing policies on oxygen therapy in COPD patients.
Injuries to the inferior vena cava and their management.

I. Turpin,D. State,A. Schwartz

DOI: https://doi.org/10.1097/00005373-197712000-00019

1977-12-01

Abstract:Injuries to the inferior vena cava are being seen with increasing frequency in the civilian population. A review of the experience at UCLA/Harbor General Hospital Medical Center over a ten year period (1966 to 1976) discloses thirty-four patients with major injuries to the inferior vena cava, with an overall mortality of 53%. The factors that appear critical to patient survival are: (1) level of injury (suprarenal versus infrarenal sites); (2) presence or absence of profound shock on admission; and (3) the speed with which diagnosis is made and treatment carried out. Technical considerations regarding identification and handling of inferior vena caval injuries are presented. The mortality rate for major inferior vena caval injuries remains distressingly high and serves as a challenge for future improvement.
[On the immunochemistry of the O antigens of Enterobacteriaceae. V. The antigen factors in isolated Salmonella O antigens].

O. Luederitz,G. O'neill,O. Westphal

Abstract:
Attenuation of postischaemic dysfunction by ischaemic preconditioning is not mediated by adenosine in the isolated rat heart.

G. Asimakis,K. Inners-mcBride,V. Conti

DOI: https://doi.org/10.1093/CVR/27.8.1522

IF: 13.081

1993-08-01

Cardiovascular Research

Abstract:OBJECTIVE The aim was to test the hypothesis that adenosine mediates the cardioprotective effects of ischaemic preconditioning in the isolated rat heart. METHODS Transient exposure of the hearts to adenosine and the A1 selective agonist, PIA, were tested for the ability to mimic the cardioprotective effects of ischaemic preconditioning in hearts that underwent 40 min normothermic ischaemic followed by 30 min reperfusion. Treated hearts were perfused with 10 or 50 microM adenosine or 10(-7) M R-phenylisopropyladenosine (PIA) for 5 min followed by a 5 min washout period. Preconditioned hearts underwent 5 min of ischaemia and 5 min of reflow prior to the 40 min ischaemic period. The ability of the adenosine receptor antagonist, BW A1433U, to inhibit the cardioprotective effects of ischaemic preconditioning was also tested. The effects of these treatments on metabolite levels and postischaemic haemodynamic function were assessed. RESULTS Adenosine (50 microM), but not PIA, resulted in enhanced accumulation of lactate after 40 min ischaemia: 122(SEM 8) v 96(5) nmol.mg-1 protein in control hearts (p < 0.002). Adenosine and PIA treatments did not significantly affect myocardial acidosis during ischaemia. Postischaemic contractile function (as assessed by percent recovery of the heart rate x developed pressure) was lower in 50 microM, but not 10 microM, adenosine treated hearts [8.8(2.2)] and PIA treated hearts [11.9(2.5)] than in control hearts [20.4(3.6)] (p < 0.01). Ischaemic preconditioning (1) lowered glycogen levels prior to the 40 min ischaemic period [57(6) v 110(18) nmol glucosyl units.mg-1 protein; p < 0.01]; (2) lowered lactate levels at the end of the 40 min ischaemic period [61(4) v 104(5) nmol.mg-1 protein]; (3) preserved myocardial pH during ischaemia [6.69(0.07) v 6.40(0.07); p < 0.01]; and (4) enhanced recovery of postischaemic contractile function [42.3(4.4)% v 19.7(6.0)%; p < 0.02]. BW A1433U did not prevent these effects of ischaemic preconditioning. CONCLUSIONS The cardioprotective effects of ischaemic preconditioning are not mediated by adenosine released during the preconditioning period in the isolated rat heart. Also, transient treatment of the heart with A1 adenosine receptor agonists can exacerbate postischaemic contractile dysfunction.
[Hearing loss].

T. Yamasoba

Abstract:
The adherence to and utility of the Global Initiative for Chronic Obstructive Lung Disease guidelines for treating COPD among pulmonary specialists: a retrospective analysis

Fortune O Alabi,Hadaya A Alkhateeb,Mukudzeishe T Zibanayi,Jica Garces,Kayla M DeBarros,Pierina S Benel Barletti,Kayla Garcia,Randall K James

DOI: https://doi.org/10.1186/s12890-023-02503-7

2023-06-19

Abstract:Background: Despite the evidence-based guidelines promoted by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), the overuse of prescription drugs to manage COPD, particularly inhaled corticosteroids (ICS), remains a persistent challenge. In this real-world study, we evaluated how patients with COPD were divided into ABCD groups based on the 2017 GOLD guidelines, determined the rate of adherence to the GOLD treatment recommendations, described the rate of ICS usage, and determined the rate of triple therapy (TT) prescription. Methods: The charts of 2291 patients diagnosed with COPD were retrospectively analyzed, of which 1438 matched the eligibility criteria. Results: The average patient age was 69.6 ± 10.9 years; 52% of patients were female. The average COPD assessment test (CAT) score was 18.3 ± 9.1. The ABCD breakdown was as follows: group A 19.5%, group B 64.1%, group C 1.8%, and group D 14.6%. All groups, except group D, showed discordance in COPD treatment relative to the proposed GOLD guidelines. Only 18.9% of group A and 26% of group B were treated in concordance with the guidelines. TT was primarily used in group D (63.3%) and overused in groups A (30.6%) and B (47.8%). ICS was overused in all groups, particularly in groups A (56.2%) and B (67.3%). Conclusion: Studies from the last decade have consistently revealed a lack of conformity between what physicians prescribe and what GOLD guidelines recommend. The excessive usage of ICS, which continues despite all the associated adverse effects and the attributable costs, is concerning. The awareness of GOLD guidelines among primary care physicians (PCPs) and respiratory specialists needs to be improved.
Cardiovascular Events According to Inhaler Therapy and Comorbidities in Chronic Obstructive Pulmonary Disease

Eun Kim,Eunyoung Lee,Ji Park,Jae Lee,Hye Choi,Bumhee Park,Seung Sheen,Kwang Park,Chin Rhee,Sang Lee,Kwang Yoo,Joo Park

DOI: https://doi.org/10.2147/copd.s433583

2024-01-20

International Journal of COPD

Abstract:Eun Kyung Kim, 1, &ast Eunyoung Lee, 2, &ast Ji Eun Park, 3, &ast Jae Seung Lee, 4 Hye Sook Choi, 5 Bumhee Park, 6, 7 Seung Soo Sheen, 3 Kwang Joo Park, 3 Chin Kook Rhee, 8 Sang Yeub Lee, 9 Kwang Ha Yoo, 10 Joo Hun Park 3 1 Department of Pulmonology, Allergy and Critical Care Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea; 2 Department of Neurology, McGovern Medical School at UTHealth, Houston, TX, USA; 3 Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, Republic of Korea; 4 Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; 5 Department of Internal Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea; 6 Office of Biostatistics, Medical Research Collaborating Center, Ajou Research Institute for Innovative Medicine, Ajou University Medical Center, Suwon, Republic of Korea; 7 Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea; 8 Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Republic of Korea; 9 Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea; 10 Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Republic of Korea &astThese authors contributed equally to this work Correspondence: Joo Hun Park, Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Worldcup Road 164, Suwon, Gyeonggi-do, 16499, Republic of Korea, Tel +82-31-219-5116, Fax +82-31-219-5124, Email ; Background: COPD coexists with many concurrent comorbidities. Cardiovascular complications are deemed to be major causes of death in COPD. Although inhaler therapy is the main therapeutic intervention in COPD, cardiovascular events accompanying inhaler therapy require further investigation. Therefore, this study aimed to investigate new development of cardiovascular events according to each inhaler therapy and comorbidities. Methods: This study analyzed COPD patients (age ≥ 40 years, N = 199,772) from the Health Insurance Review and Assessment Service (HIRA) database in Korea. The development of cardiovascular events, from the index date to December 31, 2020, was investigated. The cohort was eventually divided into three arms: the LAMA/LABA group (N = 28,322), the ICS/LABA group (N = 11,812), and the triple group (LAMA/ICS/LABA therapy, N = 6174). Results: Multivariable Cox analyses demonstrated that, compared to ICS/LABA therapy, triple therapy was independently associated with the development of ischemic heart disease (HR: 1.22, 95% CI: 1.04– 1.43), heart failure (HR: 1.45, 95% CI: 1.14– 1.84), arrhythmia (HR: 1.72, 95% CI: 1.41– 2.09), and atrial fibrillation/flutter (HR: 2.31, 95% CI: 1.64– 3.25), whereas the LAMA/LABA therapy did not show a significant association. Furthermore, emergency room visit during covariate assessment window was independently associated with the development of ischemic heart disease, heart failure, arrhythmia, and atrial fibrillation/flutter ( p < 0.05). Conclusion: Our data suggest that cardiovascular risk should be considered in COPD patients receiving triple therapy, despite the confounding bias resulting from disparities in each group. Keywords: COPD, inhaler therapy, cardiovascular event, comorbidities Chronic obstructive pulmonary disease (COPD) is a global health issue with increasing prevalence, morbidity, and mortality. 1,2 COPD coexists with many concurrent co-morbidities, including hypertension, ischemic heart disease, chronic heart failure, osteoporosis, muscle weakness, depression, and lung cancer. 3–5 Cardiovascular complications are deemed to be major causes of death in COPD. 3–5 The development of cardiovascular comorbidities in COPD is explained by several mechanisms, including lung hyperinflation, hypoxemia, pulmonary hypertension, systemic inflammation, oxidative stress, and exacerbations. 6,7 Current guidelines recommend the use of inhaled long-acting bronchodilators in symptomatic COPD patients because beneficial effects of inhaled long-acting bronchodilators including long-acting β2-agonists (LABA) and long-acting muscarinic antagonists (LAMA) in COPD have been documented in several clinical trials. 8–10 Inhaled long-acting bronchodilators can reduce the frequency and severity of acute exacerbati -Abstract Truncated-

respiratory system
Analysis of Prescription Pattern, Treatment, and Clinical Outcome in Chronic Obstructive Pulmonary Disease Patients at Tertiary Care Teaching Hospital

Shital Savaliya,Krishna Modi,Anil Singh,Kiran Piparva

DOI: https://doi.org/10.1177/09760016241258332

2024-06-16

Apollo Medicine

Abstract:Background and Aims: A major economic and social burden is associated with chronic obstructive pulmonary disease (COPD), an incurable lung illness that affects people all over the world. With a rising incidence rate, COPD is predicted to overtake all other causes of mortality by 2030. This study employs the BMI, Obstruction, Dyspnea scale, exercise tolerance (BODE) index as a multidimensional staging approach to evaluate the prescription pattern, safety, and efficacy of therapy in patients with COPD. The body mass index (BMI), forced expiratory volume in one second (FEV1), modified british medical research council questionnaire (MMRC) Dyspnoea scale, and the 6-minute walk test are among the factors that the BODE index uses to classify the severity of an illness. Methods: An observational and prospective study was conducted at a government teaching hospital’s outpatient department for one and a half years. Demographic, clinical, and treatment data were collected from patients with COPD, and severity was assessed using the BODE index. The study aimed to evaluate prescription trends, treatment effectiveness, and safety, with primary and secondary objectives. Results: Out of 100 enrolled participants, 79 completed follow-ups. Sociodemographic analysis revealed a male predominance (83.54%), with the highest prevalence in the 51–70 age group. Most patients exhibited moderate COPD severity (51.9%), based on the BODE index. Prescriptions included inhalation therapy (94.94%), predominantly combining corticosteroids and bronchodilators. Assessing treatment effectiveness, the BODE index significantly improved over 6 months ( P = 0.0002), demonstrating reduced disease severity. Adverse drug reactions occurred in 13.92% of participants, primarily mild in nature. Conclusion: The study highlights prevalent prescription patterns, emphasising inhalation therapy, and demonstrates the effectiveness and safety of the selected treatments using the BODE index. The findings underscore the importance of tailored therapeutic approaches in COPD management.

Immunodiffusion and fluorescent antibody methods to distinguish rod from coccoid forms of a species ofArthrobacter

Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea

Escalation Time to Open Triple Combination Therapy from the Initiation of LAMA versus ICS/LABA in COPD Management: Findings from Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea (CITRUS) Study

A note on certain cranial indices of the Sterkfontein skull No. 5.

The current status of chronic obstructive pulmonary disease awareness, treatments, and plans for improvement in South Korea: a narrative review

The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease

The effects of different inhalation therapies on less symptomatic chronic obstructive pulmonary disease patients in a Chinese population: a real-world study

Real-World Effectiveness of Inhalation Therapy Among Patients With Symptomatic COPD in China: A Multicenter Prospective Study

Treatment patterns in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)

Neues zu den diätetischen Schriften des Rufus von Ephesos.

Overuse of long-acting β2-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns

Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world study

Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea

Korean physician prescription patterns for home oxygen therapy in chronic obstructive pulmonary disease patients

Injuries to the inferior vena cava and their management.

[On the immunochemistry of the O antigens of Enterobacteriaceae. V. The antigen factors in isolated Salmonella O antigens].

Attenuation of postischaemic dysfunction by ischaemic preconditioning is not mediated by adenosine in the isolated rat heart.

[Hearing loss].

The adherence to and utility of the Global Initiative for Chronic Obstructive Lung Disease guidelines for treating COPD among pulmonary specialists: a retrospective analysis

Cardiovascular Events According to Inhaler Therapy and Comorbidities in Chronic Obstructive Pulmonary Disease

Analysis of Prescription Pattern, Treatment, and Clinical Outcome in Chronic Obstructive Pulmonary Disease Patients at Tertiary Care Teaching Hospital